- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Camurus AB
- Número de telefone: +46 46 286 57 30
- E-mail: medicalinfo@camurus.com
Locais de estudo
-
-
-
Aachen, Alemanha, 52074
- Recrutamento
- Universitaetsklinikum Aachen
-
Leipzig, Alemanha, 04103
- Recrutamento
- Universitaetsklinikum Leipzig
-
Magdeburg, Alemanha, 39110
- Recrutamento
- Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
-
München, Alemanha, 81667
- Ainda não está recrutando
- Medicover Neuroendokrinologie MVZ
-
Münster, Alemanha, 48149
- Ainda não está recrutando
- Universitätsklinikum Münster
-
Würzburg, Alemanha, 97080
- Recrutamento
- Universitätsklinikum Würzburg
-
-
-
-
-
Leeds, Reino Unido, LS9 7TF
- Ainda não está recrutando
- St James's University Hospital - Leeds Teaching Hospitals NHS Trust
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
The study will enroll patients with acromegaly who are considered for treatment with octreotide subcutaneous depot and patients with acromegaly who have already initiated octreotide subcutaneous depot treatment. The study will be conducted in Germany, the UK, and the US.
Descrição
Inclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for acromegaly
Exclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly
- Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
Prazo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time.
Prazo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with IGF-1 ≤1×ULN over time.
Prazo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in GH levels over time.
Prazo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with GH levels <1.0 μg/L over time.
Prazo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale.
Prazo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale.
Prazo: From enrollment to the end of treatment at 2 years
|
The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL).
Prazo: From enrollment to the end of treatment at 2 years
|
The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
Prazo: From enrollment to the end of treatment at 2 years
|
The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire.
Prazo: From enrollment to the end of treatment at 2 years
|
The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HS-24-799
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .